Oxidation is a chemical process ubiquitous in nature that involves the loss of one or more electrons from one atom to a second one known as an oxidant. Oxidants are introduced through endogenous processes such as the breakdown of glucose for energy by mitochondria or via external agents including chemical toxins, air pollution, and diet. Oxidant-promoting processes activate molecular signaling pathways that trigger the production of toxic free radicals and other potentially destructive reactive oxygen species (ROS).¹⁴ These processes are regulated by a molecular defense system comprised of antioxidant enzymes and non-enzymes that maintain redox homeostasis and prevent cell damage. When levels of ROS and/or other pro-oxidant molecules exceed the capacity of available antioxidants to counteract their effects, OXS occurs. OXS is a fundamental molecular mechanism of aging and the organism’s capacity to counteract it is essential to physical wellbeing, longevity, and survival.¹⁶ OXS also triggers pro-inflammatory signaling pathways (and vice versa)^17,18 and is known to play a role in a variety of diseases including diabetes, cardiovascular illnesses, and neurodegenerative conditions.^16,17,19,20

Of all the organs in the body, the brain is perhaps the most vulnerable to damage from OXS because of its high glucose and oxygen utilization and high concentration of peroxidation-susceptible lipid cells.²¹ Consequences of OXS in the central nervous system include increased blood-brain barrier permeability, disruption of neurogenesis, impairment of synaptic plasticity, alterations of neurotransmission, and remodeling of neural morphology (for reviews, see Schiavone et al.⁹ and Uttara et al.²²). Aging is associated with increasing protein oxidation and diminishing levels of antioxidant enzymes in the brain²³ and these changes are potentiated by various disease processes. OXS is also implicated in neuronal death and erosion in neurodegenerative processes including prodromal dementia and Alzheimer’s and Parkinson’s disease.^24-30

OXS can be measured using a variety of biomarkers—each with its own advantages and disadvantages—and detailed recent reviews of these methods are available.^31-35 In brief, the most common approaches aim to quantify either antioxidant capacity or the degree of oxidative damage present in a biosample. Antioxidant capacity refers to the ability of cells to counteract effects of oxidants and is estimated in vitro. Colorimetric and fluorometric probe assays can be used to measure the capacity of a sample to reduce oxidant molecules with the degree to which the oxidant agent changes color or fluorescence indexing the antioxidant capacity of the cells. The primary limitation of these methods is that the strength of association between in vitro measurement and in vivo antioxidant capacity is unknown. Alternatively, many studies have focused on biomarkers of oxidative damage to lipid, protein or DNA molecules. Oxidative damage to lipids can be estimated with assays for compounds called isoprostanes that are produced in vivo from peroxidation of lipid cells. F₂-Isoprostanes are widely used because they are chemically stable, specific products of peroxidation, present in detectable amounts in all normal tissues and bodily fluids, and unaffected by lipid content in the diet. F₂-Isoprostanes have also been shown to increase substantially in animal models of oxidant injury,³⁴ and elevated levels have been observed in patients with various OXS-related diseases. Similarly, protein oxidation results in the introduction of carbonyl groups into proteins which can be indexed using protein carbonyl assays or mass spectroscopy.³⁵ One intriguing aspect of protein carbonylation research are the unique opportunities it for integrating data on protein modification with genomic and methylomic data to elucidate biological disease pathways spanning different levels of ”–omic” analysis. At the genomic level, OXS-related DNA damage is commonly studied by examining oxidation of the DNA nucleobase guanine which yields 8-hydroxy-2′-deoxyguanosine (8-OH-dG) and 8-hydroxyguanosine; 8-OH-G). The primary limitation of this approach is that it offers only a global measure of DNA damage and cannot implicate specific genes or the amount of damage to a particular region of interest. Furthermore, regardless of which of these approaches is used, it is impossible to determine to what extent observed oxidative damage is due to the intensity of the ROS attack or the antioxidant capacity of the cell at the time of the attack. More clinical studies evaluating change over time in measures of both antioxidant capacity and oxidative damage in patients and controls are needed to clarify this complex interplay.

Although, to our knowledge, no studies have directly examined the effects of trauma exposure on measures of OXS in humans, a growing body of research suggests that less severe psychological stress—especially chronic stress—promotes OXS throughout the body.^36,37 Elevated blood biomarkers of OXS have been found in chronically-stressed caregivers, with higher levels of perceived stress associated with higher levels of oxidative damage to RNA and lipid cells.³⁸ In one study, life stress at work and home was found to be a stronger predictor of suppressed antioxidant activity than other established oxidant-promoting factors such as cigarette smoking, alcohol consumption, poor diet, and exposure to ultraviolet radiation.³⁹ Elevated blood biomarkers of OXS have also been found in college students during periods of examination stress (e.g., Cohen et al.,³⁷ Nakhaee et al.,³⁸ and Sivonova et al.⁴¹) and in bereaved individuals following the loss of a spouse or close relative.⁴³ Another study showed that cortisol levels mediated the relationship between perceived stress and OXS damage in chronically stressed caregivers.³⁸ Links between OXS and various stress-related psychiatric diagnoses have also been found. For example, studies have shown that clinically depressed patients show elevated levels of oxidative DNA damage and suppressed antioxidant activity with the degree of damage covarying with depression severity even after controlling for behavioral factors.^44-47 Similarly, studies of patients with anxiety disorders have shown evidence of elevated lipid peroxidation in generalized anxiety disorder⁴⁸ and suppressed antioxidant activity in panic disorder.⁴⁹

Animal models offer insight into potential mechanisms of association between psychological stress and OXS and, in turn, the effects of OXS on the brain. Oxidative DNA damage can be classically conditioned in rats through pairing of pain with administration of an oxidizing agent.^50,51 Further, prolonged restraint induces generation of ROS in peripheral blood cells and these effects can be partially reversed by anxiolytic agents.⁵² Conversely, inducing ROS production through pharmacologic and non-pharmacologic methods produces anxiety-like behavior in rats.^53,54 In one noteworthy study that featured a novel animal model of PTSD, Wilson and colleagues⁵⁵ studied effects of acute and chronic stress on OXS in rats using an extended 31-day stress protocol. Biomarkers of OXS and antioxidant activity were measured throughout the study and later in post-mortem analysis of brain and adrenal tissue. Compared to controls, rats in the stress condition exhibited slower growth, higher plasma corticosterone levels, greater anxiety-like behavior on an elevated plus-maze task, and a dose-response relationship between the duration of the protocol and levels of ROS. Post-mortem analysis of brain tissue revealed elevated levels of ROS and other byproducts of OXS in the hippocampus and pre-frontal cortex. Together, these findings demonstrate links between environmental stress and OXS and provide new insights into the effects of OXS on brain regions implicated in PTSD and other psychiatric conditions.

Chronic PTSD is a stress-perpetuating syndrome characterized by hallmark episodes of sensory-memory reexperiencing of the traumatic event(s). Intrusions and flashbacks are accompanied by phasic activation of fear-related neurocircuitry,⁵⁶ elevated peripheral autonomic nervous system activity,^57,58 and enhanced cortisol and catecholamine output.^59-62 In some patients, reexperiencing symptoms occur quite frequently. For example, one study found an average of 30 intrusions per week in patients awaiting treatment.⁶³ Onset of intrusions can be spontaneous or triggered through exposure to stimuli reminiscent of the trauma,^64,65 anniversaries of the event,⁶⁶ or other adverse life events.⁶⁷ These events occur against a backdrop of tonic hyperarousal characterized by sleep disruption, hypervigilance, anger, and dysphoria. Furthermore, chronic PTSD tends to be associated with other psychiatric comorbidities, most commonly, major depression, and anxiety- and substance-related disorders.^68-70 Thus, in chronic patients, a condition that often begins as an acute anxiety reaction evolves into a pervasive and persistent illness with systemic impacts throughout the body—a form of persistent life stress—with possible consequences including neurodegeneration and other forms of accelerated cellular aging.

The notion that trauma is associated with accelerated cellular aging has a foundation in literature and historical observations dating back hundreds of years. One famous example was Marie-Antoinette whose hair reportedly turned white with fear the night before her execution by guillotine in 1793. This phenomenon, often associated with intense fear or grief, has been reified in the medical nomenclature as “Marie-Antoinette Syndrome.”⁷¹ Interestingly, it is believed to occur when hydrogen peroxide produced by OXS in the hair follicle causes the hair to lose its pigment, i.e., “the free radical theory of graying.”⁷² Jelinek⁷³ offered a fascinating review of this and other accounts of accelerated aging which together suggest that traumatic stress can render visible and permanent changes in the appearance of hair, skin, other physical attributes—all changes normally associated with aging, and all with established links to OXS.

The complex defense network of anti-oxidant enzymes and other molecules that respond to excessive accumulation of ROS is regulated by an equally sophisticated network of genes that confer individual differences in OXS response. Candidate gene and genomewide association studies (GWAS) in various species have linked numerous polymorphisms to OXS resistance⁹⁵ and twin studies in humans have found levels of peripheral biomarkers of OXS to be highly heritable.⁹⁶ Though OXS-related genes have been the focus of extensive research in neurodegenerative diseases, relatively few studies have examined their possible association with anxiety- or stress-related phenotypes. One important exception to this was a study by Hovatta et al⁹⁷ who examined gene expression levels across various brain regions in strains of mice that were genetically-modified to manifest different levels of anxious behavior. By experimentally manipulating OXS-related gene expression, Hovatta et al⁹⁷ showed that two genes that produce anti-oxidant enzymes (glyoxalase 1 and glutathione reductase 1) in the cingulate cortex modulated anxious behavior on several validated laboratory tasks. Subsequent animal studies have shown that the association between glyoxalase 1 and anxious behavior may be mediated by methylglyoxal, a GABA_A receptor agonist (the latter being the primary molecular target of the benzodiazepine class of anxiolytic drugs).⁹⁸

Other evidence supporting a possible link between OXS-related genes and stress-related phenotypes came from a GWAS of PTSD, which implicated a gene with a known role in moderating OXS as a significant risk locus for the disorder. Logue et al⁹⁹ performed a GWAS using a sample of trauma-exposed veterans and their spouses and found a genome-wide-significant association between a SNP in the Retinoic Acid Orphan Receptor Alpha gene (RORA; rs8042149) and a diagnosis of PTSD in Caucasians. Subsequently, an independent research group published a replication of the rs8042149-PTSD association,¹⁰⁰ and in another study, Miller and colleagues¹⁰¹ found that RORA SNP rs17303244 was associated with diagnoses of the fear spectrum (i.e., defined by panic, agoraphobia, specific phobia, and obsessive-compulsive disorders). Prior to this, RORA had been implicated in GWAS studies as a risk factor for various other psychiatric conditions including attention-deficit hyperactivity disorder,¹⁰² bipolar disorder,¹⁰³ depression,¹⁰⁴ and autism.^105,106

The RORA protein has four isoforms, one of which is expressed primarily in the central nervous system and found in cell nuclei in brain regions including the frontal cortex, hippocampus, and hypothalamus.¹⁰⁷ Its expression is activated during OXS,¹⁰⁸ and it protects neurons from apoptosis by increasing the expression of genes involved in the clearance of ROS (Gpx1 and Prx6).¹⁰⁹ Miller et al¹⁰¹ hypothesized that the neurons of individuals carrying the RORA risk variant(s) mount an abnormal response to the OXS associated with PTSD, leading to neurodegeneration and functional abnormalities in regions of the brain subserving fear- and anxiety-related psychopathology. Consistent with this, RORA SNP variants have been linked in genetic-imaging studies to global measures of human cortical thickness and fractional anisotropy of cerebral white matter,¹¹⁰ as well as to volume of the entorhinal cortex, the main interface between the hippocampus and neocortex.¹¹¹ Moreover, in the latter study, RORA SNPs were highly correlated with Alzheimer’s disease-related atrophy. These findings point to the potential value of examining the role that RORA variants and other OXS-related genes play in moderating the effects of PTSD on neural integrity and brain morphology.

Recent advances in the field of molecular genetics offer new directions for research into mechanisms of accelerated aging and its possible links to PTSD and OXS. Telomeres, which are nucleotide sequences located at the ends of chromatids that erode with normal aging as a result of repeated DNA replication, offer one potential metric of this process. Telomere shortening is accelerated by OXS through its effects on telomerase—an enzyme that maintains telomere length—whereas antioxidants decelerate telomere shortening and prolong telomerase activity.¹¹² Preliminary studies linking adverse life events^113,114 and PTSD to telomere shortening^115-117 point to the value of using telomeres in future research to measure accelerated aging in PTSD. For example, one recent cross-sectional study found lower relative leukocyte telomere length in veterans with probable PTSD than age-matched controls.¹¹⁸

DNA methylation profiling offers another approach. DNA methylation is the addition of a methyl group to the DNA base cytosine in regions known as CpG sites where a cytosine nucleotide occurs next to a guanine nucleotide (i.e., a C—phosphate—G sequence). Methylation in the promoter region of genes causes gene silencing and thereby represents a process by which gene expression is regulated. Methylation levels generally decrease with age, though certain regions show opposite effects. These processes are influenced by OXS via the oxidation of guanine in the CpG sequence.^119-121 Thus, as with telomeres, the methylation status of certain genetic loci can be used to index cellular age and the rate of cellular aging. In a landmark study on the development of an “epigenetic clock”, Horvath¹²² analyzed methylation data from 8,000 samples of 51 different tissue types and identified 353 sites that together offered a near-perfect predictor of age for non-cancerous tissues. Future studies of the accelerated aging hypothesis in PTSD may greatly benefit from the insights offered by this type of epigenetic clock.

In the treatment domain, an obvious direction for future research is to explore whether antioxidant compounds can prevent or slow OXS-related processes. Evidence supporting antioxidant supplements comes primarily from (a) in vitro studies demonstrating the antioxidant efficacy of Vitamins A, C, and E, (b) epidemiological nutrition studies showing the health benefits of antioxidant-rich diets (e.g., in reducing risk for Alzheimer’s disease¹²³), and (c) mouse models showing that antioxidant supplements reduce OXS-related mitochondrial damage.¹²⁴ A few clinical studies have also yielded positive results. For example, one randomized trial over 500 veterans with mild to moderate Alzheimer’s disease found that vitamin E significantly reduced the rate of functional decline and decreased caregiver burden over a two-year follow-up period compared to placebo.¹²⁵ Unfortunately, the majority of human clinical trials of antioxidant therapeutics have shown little benefit or inconclusive results.

There are a number of plausible explanations for the gap between the promise of antioxidant therapies and the generally disappointing findings of clinical trials (for a review, see Firuzi et al.).¹²⁶ For one, it is likely that not all patients will benefit equally from antioxidant therapy. Given the substantial genetic individual differences in OXS reactivity, pharmacogenically-informed approaches may be needed to better match patients to specific antioxidant therapeutics. Another consideration is that most of the antioxidants studied operate globally with poor target specificity, whereas OXS damage may be limited to specific brain regions, cells types, or even certain membranes within cells. An antioxidant compound that offers a more targeted delivery is the mitochondria-targeted antioxidant SS31, which has been shown, in vitro, to protect neurons from neurotoxins.¹²⁷ Similarly, L-carnitine, which works as a free radical scavenger, readily crosses the blood–brain barrier¹²⁸ and has been found to reduce OXS damage in brain tissue, and enhance functional outcomes in patients with mood disorders, neurometabolic disorders, and Alzheimer’s disease.^129-131 Thus, more targeted treatments and/or pharmacogenetically-informed approaches remain important directions for future intervention studies.

We have reviewed evidence suggesting that chronic PTSD constitutes a form of persistent life stress that potentiates OXS and accelerates cellular aging. However, the evidence that led to this hypothesis is indirect and no studies have established a causal link between PTSD and OXS, or demonstrated that PTSD confers a greater risk for OXS and accelerated aging relative to other mental illnesses or stress-related conditions. Furthermore, we recognize though that OXS is just one of many possible molecular mechanisms for accelerated aging and note that other pathways such as pro-inflammatory signaling pathways that are reciprocally related to OXS are undoubtedly involved as well. We focused on OXS because, despite the evidence that we and others have laid out for its role in stress-related mechanisms of psychopathology and disease, it has received relatively little attention in the field of traumatic stress. In doing so, we hoped to elevate awareness of the relevance of OXS to PTSD and its comorbidities and to stimulate new research on accelerated aging in PTSD and other disorders of the trauma- and stressor-related disorder spectrum. Finally, given the seemingly ubiquitous role of OXS in aging and disease, it is untenable to conceptualize it as stress- or PTSD-specific mechanism. Rather, OXS is more appropriately viewed as molecular mechanism of disease and aging common to many illnesses but one that it may also be initiated or potentiated by traumatic stress, chronic PTSD and related conditions. As such, it represents a potentially useful avenue for future PTSD-related biomarker research and treatment development.